24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Medical Disorders
Resources
Basic InformationLookupsLatest News
Losing Sense of Smell Can Worsen Life in Many Ways: StudyCoronavirus Cases Top 2,700 in China, While 5th U.S. Case Is ConfirmedGene Test Might Spot Soccer Players at High Risk for Brain TroubleMany Americans in the Dark About Eye HealthFirst Clinical Studies Find Wuhan Virus Closely Resembles SARSA Flu Shot May Spare Your Young Child a Hospital VisitMany of America's Most Critical Workers Are Short on Their ZzzsFaulty Immune System May Lead to Lung CancerOnly 1 in 4 Older Cardiac Patients Get Rehab TherapyPrescription-Strength Steroid Creams Sold Over-the-Counter Can Be DangerousWhat You Need to Know Now About the Wuhan VirusThe Damage of Vaccine MisinformationAHA News: What's Blood Type Got to Do With Clot Risk?Racism Linked to Faster Aging Among BlacksScientists Trace Coronavirus Outbreak to SnakesBlacks, Hispanics More Likely to Have Better Outcome After 'Bleeding' StrokeNew Drug Could Help Stop Blindness From Thyroid Eye Disease'Yo-Yo' Blood Pressure Numbers in Youth a Bad Sign for Health LaterFlame Retardants, Pesticides Remain Threat to U.S. Health: StudyDon't Want a 2nd Heart Attack? Lose the Belly FatHow to Keep Those Blood Vessels PumpingScreening for Chinese Coronavirus to Start at 3 Major Airports: CDCDo You Take Warfarin? Time of Day Might Not MatterHealth Tip: Signs of Food PoisoningSepsis Causes Far More Deaths Worldwide Than ThoughtMillennials Most Likely to Skip Flu Shot, Believe 'Anti-Vaxxer' Claims: PollResearchers Alter Mosquitoes to Resist Dengue InfectionMany Americans Are Inactive, With Southerners Faring WorseVirtual Reality Can Bring Real-Life PainAre Doctors Discarding 'Injured' Kidneys That Might Be Used for Transplant?Nerve Stimulation Therapy Could Cut Fibromyalgia PainWhich Obesity Surgery Is Right for You?Brake Dust Another Driver of Air PollutionWhat Works Best to Help Men With Overactive Bladder?More Studies Link Vaping to Asthma, COPDCertain Diabetes Meds May Lower Gout Risk, TooHeart Transplants From Donors With Hepatitis C May Be Safe: StudyClimate Change May Translate Into More Fatal InjuriesAll in the Timing: Many Get Knee Replacement Too Late or Too SoonHealth Tip: Preparing for an UltrasoundLow Levels of Key Blood Cells Could Signal Higher Death RiskGyms Are Fertile Ground for GermsTwo More Heartburn Meds Recalled Due to Possible CarcinogenZika Damage Showing Up in Babies Deemed 'Normal' at BirthHealth Tip: Coping With Winter NosebleedsHeart Disease May Up Risk of Kidney FailureFlu Cases Surge Early, Could a Tough Season Lie Ahead?Cluster of Unhealthy Risk Factors Could Raise Odds of Recurrent Blood ClotsAHA News: Worried About Dementia? Check This Blood Pressure NumberNew Study Reports Alarming Surge in E-Scooter Accidents
Questions and AnswersLinks
Related Topics

Diabetes

Drug Trio Could Give Patients With Cystic Fibrosis a New Option

HealthDay News
by -- Robert Preidt
Updated: Nov 1st 2019

new article illustration

FRIDAY, Nov. 1, 2019 (HealthDay News) -- A three-drug combo that significantly improves lung function in cystic fibrosis patients could benefit 90% of people with the life-threatening disease, a new study suggests.

It included patients with a single copy of the most common genetic mutation for the disease.

Results of the international phase 3 clinical trial led the U.S. Food and Drug Administration to approve the therapy last month. The findings were published Oct. 31 in the New England Journal of Medicine.

"This should be a major cause for celebration," Dr. Francis Collins, director of the U.S. National Institutes of Health, wrote in an editorial accompanying the new study.

Cystic fibrosis (CF) is a progressive genetic disease that causes thick mucus to build up in the lungs, digestive tract and other parts of the body, resulting in severe respiratory and digestive problems and other complications such as infections and diabetes.

"Although there are over a thousand different disease-causing mutations, nearly 90% of people with cystic fibrosis have at least one copy of the most common mutation, the Phe508del CFTR allele," said study corresponding author Dr. Raksha Jain. She's director of the Adult Cystic Fibrosis Center at University of Texas Southwestern Medical Center in Dallas.

About 80,000 people worldwide have mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) protein, according to Jain. People inherit a gene from each parent that encodes the CFTR protein.

"This three-drug combination was highly effective in people with cystic fibrosis who inherited the Phe508del CFTR mutation, improving health outcomes and symptoms," Jain said in a university news release.

The study, conducted at 115 sites in 13 countries, included 403 patients with one mutated copy of the gene.

Patients were randomly selected to receive either the elexacaftor-tezacaftor-ivacaftor combo (Trikafta) or a placebo. The trial was co-sponsored by Vertex Pharmaceuticals, which makes the drug combo. Its list price is $311,500 a year.

Patients' lung function was assessed at four and 24 weeks. Compared to those in the placebo group, patients who took Trikafta had significantly improved lung function at both checkups.

Symptom flare-ups were 63% lower in the Trikafta group, and these patients also had better questionnaire scores on quality of life and respiratory symptoms than the placebo group, according to the study.

Excessive amounts of salt in sweat is a hallmark of cystic fibrosis. People in the Trikafta group had a lower concentration of salt in their sweat than those in the placebo group, which suggests that the therapy targets the disease's underlying cause, Jain said.

For his part, Collins said that enthusiasm over the study's results should be tempered by the knowledge that 10% of patients won't be helped by this therapy.

"We must not abandon the patients with cystic fibrosis who … will not have a response to these drugs," he wrote. "The 'best day ever' for all of us traveling down this long road together will be the day when the more than 70,000 persons with cystic fibrosis worldwide do not need to take drug therapy at all and there finally is a permanent cure for cystic fibrosis that works for everyone."

And 1% of the Trikafta group stopped taking the drugs due to adverse events, the study authors noted. Further research is needed to learn more about potential side effects, Jain said.

She was also involved in a study that assessed Trikafta on patients with one or two copies of the Phe508del CFTR allele. That study was recently published in The Lancet medical journal.

Jain is presenting results of both studies this week at the North American Cystic Fibrosis Conference, in Nashville, Tenn.

"The CF community is working hard to find highly effective therapies for people who are not eligible for this treatment because they don't have the appropriate gene mutation," she said.

More information

The American Lung Association has more on cystic fibrosis.